Merz Aesthetics, a medical aesthetics business, announced actress, director, and producer Salma Hayek Pinault as its first global brand ambassador for Ultherapy PRIME, a micro-focused ultrasound platform for personalized, non-invasive skin lifting. 

Ultherapy PRIME is US Food and Drug Administration-cleared to lift the skin on the neck, under the chin, and the eyebrows, as well as to smooth lines and wrinkles on the décolleté. Visible results can be achieved in one session, with no downtime, and can last up to a year or more. 

“With her unwavering commitment to authenticity, Hayek Pinault trusts Ultherapy PRIME for a personalized, natural-looking lift, with results that can last up to a year or more. This collaboration reflects a shared belief in empowering individuals to look and feel their best to fuel confidence worldwide,” according to a release from Merz Aesthetics.

Hayek Pinault is an Academy Award-nominated actress and Emmy-winning director, also celebrated for her work as a producer. As an advocate for authentic self-expression and looking great at any age, she encourages others to embrace treatments that enhance their natural features.

“Self-care is essential. Years on screen have taught me to embrace my journey and seek treatments that enhance my natural beauty,” says Hayek Pinault in a release. “Ultherapy PRIME boosts my production of collagen and elastin exactly where I need it, giving me a long-lasting, natural-looking lift. It’s non-invasive, takes only one session, and has zero downtime. It is the future of beauty, and that’s why I can’t stop talking about it.” 

Evolution of Ultherapy

The Ultherapy PRIME platform is the evolution of Ultherapy. Ultherapy PRIME further advances nonsurgical skin lifting by combining a micro-focused ultrasound platform with real-time imaging. 

Since its September 2024 launch, Ultherapy PRIME has already been cleared in over 80% of Nerz Aesthetics’ targeted markets, with more approvals expected in 2025.

“We are proud and excited about the recent launch of Ultherapy PRIME, our next-generation platform for non-invasive skin lifting and a testament to our unwavering commitment to delivering meaningful innovations to our customers,” says Bob Rhatigan, CEO of Merz Aesthetics, in a release. “As we continue to expand the global footprint of this launch, we are thrilled to collaborate with Hayek Pinault as the first-ever global brand ambassador for Ultherapy PRIME.” 

Photo caption: Salma Hayek Pinault

Photo credit: Merz Aesthetics

Related Read:

Cynosure Lutronic, specializing in energy-based medical aesthetic devices, announced the Health Canada clearance of XERF, a radiofrequency device designed for skin tightening treatments.

XERF tightens skin without the need for numbing, needles, or downtime, according to a release from the company. Key features include: 

• Single Shot, Multi-Frequency Monopolar RF Technology: This combines 6.78 MHz and 2 MHz frequencies, enabling providers to precisely deliver energy at multiple tissue depths, heating the fibrous septae to generate both immediate and lasting skin tightening results.
• Wave Fit Pulse and Advanced Integrated Cryogen Delivery Cooling Technology: These technologies are designed to work in tandem to regulate energy delivery and maintain optimal surface temperature to ensure a comfortable treatment without the need for numbing.
• Innovative Spider Pattern Tip: Designed to reduce skin edge effects, this tip ensures a controlled treatment environment, increasing treatment efficacy and patient safety.

“The clearance of XERF in Canada marks an exciting milestone for Cynosure Lutronic as we expand our presence in North America,” says Lowinn Kibbey, president, North America at Cynosure Lutronic, in a release. “As patients continue to seek effective treatments to tighten and revitalize their skin, they often face challenges with discomfort or downtime. With XERF, we are thrilled to offer a solution that delivers exceptional results while providing a more comfortable experience.”

Jordan V. Wang, MD, MBE, MBA, medical director of Laser & Skin Surgery Center of Pennsylvania and medical research director at the office of Roy Geronemus, MD, adds in a release, “As a fellowship-trained cosmetic dermatologist, we prioritize treatments in our clinic that can consistently deliver results with minimal risk and downtime. XERF incorporates the newest technology to safely deliver energy deep into the skin, while offering intelligent cooling for superior protection and patient comfort.” 

The radiofrequency device for skin tightening treatments launched in 2024 and is currently sold in Korea, Japan, and Hong Kong. With its Health Canada clearance, Cynosure Lutronic is prioritizing Canada as XERF’s first North American launch market.

ID 277331564 © Yriy Granovskuy | Dreamstime.com

Related Read:

BTL Industries has announced the launch of EMFACE Eye, a new device intended to treat under-eye aging through non-invasive means. EMFACE Eye marks an expansion of the company’s EMFACE platform and is designed to restore muscle tone and soft tissue support in the periorbital region without the need for surgery or injectables.

The launch follows significant growth for the company, with EMFACE surpassing 1 million treatments globally and a 70% year-over-year sales increase in North America in Q1 2025.

A Focus on the Under-Eye Area

The under-eye region has traditionally posed challenges for non-surgical aesthetic procedures due to its delicate anatomy and tendency toward issues like puffiness, dark circles, and volume loss. EMFACE Eye targets the lower orbicularis oculi muscle to lift and support soft tissue, offering an alternative or adjunct to injectables, according to the company.

BTL reports that in a typical 20-minute session, patients experienced a 1.4mL reduction in under-eye volume, a 28% reduction in crow’s feet, and a 64% decrease in dark circles—all without downtime.

Clinical Perspective and Platform Expansion

Melanie Palm, MD, MBA, a cosmetic dermatologist in California, noted that EMFACE Eye provides meaningful structural support to the infraorbital area, reducing fat pseudo-herniation and improving overall appearance. “As a cosmetic dermatologist with a sizeable injectable practice, this is exactly what I’ve been waiting for. The results include noticeable brightening of the under-eye and buttressing of the infraorbital fat pad, significantly reducing fat pseudo-herniation. Emface restores structure and function to the facial anatomy in the most natural way, so we can count on superior results that drive high patient satisfaction,” said Palm.

With the Eye applicators, the EMFACE platform now supports full-face aesthetic treatment, including forehead lifting, jawline sculpting, and periorbital enhancement. According to BTL, this enables a layered, non-invasive approach that integrates well with existing injectable protocols.

BTL Eyes Continued Growth in Aesthetic Market

EMFACE Eye’s release reinforces BTL’s position in the growing non-invasive facial aesthetics segment. The company says the platform is designed to meet increasing patient demand for natural-looking results without surgical intervention or downtime.

Photo: ID 175406582 © Karel Noppe | Dreamstime.com

Recent reports have noted that benzoyl peroxide, a common acne-fighting ingredient available by prescription and over the counter, has the potential to break down into benzene.

The US Food and Drug Administration (FDA) alerted the public and industry to the results of new agency testing of 95 acne products containing benzoyl peroxide for possible benzene contamination. The FDA concluded that a limited number of products should be recalled at the retail level; more than 90% of tested products had undetectable or extremely low levels of benzene.

The FDA initiated independent testing following receipt of third-party testing results submitted to the agency that raised concerns about elevated levels of benzene in certain acne products containing benzoyl peroxide. Testing results indicate fewer products with benzene contamination than the third-party findings.

“Research on this issue is ongoing, and we continue to monitor new findings to ensure dermatologists and patients have the most accurate and up-to-date information,” says American Academy of Dermatology president Susan C. Taylor, MD, FAAD, in a release. “…While some studies suggest potential connections between benzene and an elevated risk for certain diseases, like cancer, the potential risk is still being investigated.

Recalls at the Retail Level

The FDA’s findings led to several companies recalling their products at the retail level. These include La Roche-Posay Effaclar Duo Dual Action Acne Treatment, Walgreens Acne Control Cleanser, Proactiv Emergency Blemish Relief Cream Benzoyl Peroxide 5%, Proactiv Skin Smoothing Exfoliator, SLMD Benzoyl Peroxide Acne Lotion, and Walgreens Tinted Acne Treatment Cream.

Additionally, the manufacturer of another benzoyl peroxide acne product, Zapzyt Acne Treatment Gel, agreed to voluntarily recall this product due to the elevated level of benzene found during its own testing.

Benzene is a chemical formed in nature and from human activities. It is also a natural part of crude oil, gasoline, and cigarette smoke. Exposure to benzene can increase the risk of cancer. Further information regarding benzene in drugs can be found here.

“If you have one of the recalled products listed on the FDA website, there is no immediate cause for concern. This is a retail-level recall, meaning stores and online retailers have been asked to stop selling these products. The FDA has not recommended that the public take any action at this time,” says Taylor in a release. 

FDA Testi Finds Benzene Contamination in Six of 95 Treatments

The FDA’s testing used validated test methods and assessed all benzoyl peroxide products identified by third-party laboratories as having elevated benzene levels that FDA was able to purchase at the time of testing, as well as additional marketed products. The FDA tested a total of 95 acne treatment products containing benzoyl peroxide and found six products with elevated levels of benzene. The FDA notes that some of these six products are approaching their expiration dates and recommends consumers check their products and throw away products that are beyond their expiration date.  

The FDA intends to publish the full results of its testing, including data and information on testing methods, in one or more peer-reviewed journals in the coming months. 

The American Academy of Dermatology recommends that patients follow best practices for storing and handling products containing benzoyl peroxide and consult their dermatologist if they have any concerns. To minimize risk:

• Store products according to the manufacturer’s instructions at room temperature or cooler conditions (eg refrigerated).
• Replace products that contain benzoyl peroxide every 10-12 weeks.
• Benzoyl peroxide products should be discarded if exposed to high temperatures (eg greater than 78°F).

ID 285250835 © Luchschen | Dreamstime.com

InnoCare Pharma announced its novel TYK2 inhibitor ICP-488 deve,loped for the treatment of patients with moderate-to-severe plaque psoriasis, has demonstrated efficacy in treating psoriasis patients at both 6 mg QD and 9 mg QD doses. 

Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for moderate-to-severe psoriasis patients.

The company released the data at the 2025 American Academy of Dermatology Annual Meeting as a late-breaking oral presentation.

Late-breaking Oral Presentation

In the phase 2, randomized, double-blinded study 129 psoriasis patients were randomized into three groups to receive once daily oral doses of ICP-488 at 6 mg, 9 mg, or placebo for 12 weeks. The primary endpoint was the percentage of subjects who achieved at least a 75% improvement from baseline in the Psoriasis Area and Severity Index score (PASI 75) at week 12.

At week 12, the percentage of patients achieving PASI 75 was significantly superior in the ICP-488 6 mg QD group (77.3%) and the 9 mg QD group (78.6%) than that of the placebo group (11.6%) (P<0.0001); the percentages of subjects achieving PASI 90 and sPGA of 0 (clear) or 1 (almost clear) were also significantly higher in the ICP-488 6 mg QD group (36.4%, 70.5%) and 9 mg QD group (50.0%, 71.4%) compared to the placebo group (0%, 9.3%)(P<0.0001). 

All treatment emergent adverse events and treatment-related adverse events and were mild or moderate.

Psoriasis is a chronic, recurrent, inflammatory, and immune-mediated systemic disease influenced by genetic and environmental factors, significantly impacting patients’ quality of life.

ID 97216428 © Hriana | Dreamstime.com

Related Read:

Key Takeaways:

1. Topical Formula Reduces Retinoid Irritation – A study found that combining tretinoin with a skin-barrier-supporting ingredient significantly reduced skin irritation.
2. Improved Tolerance Without Compromising Efficacy – The formulation decreased redness by 68% and dryness by 47%, with no reported adverse events.
3. Further Research Needed – While initial results are promising, researchers suggest larger, controlled studies to confirm the findings.

Retinoids are the gold standard for anti-aging, but the redness, peeling, and irritation can deter patients from continued use. But what if you could get the glow that retinol provides without the irritating side effects?

A new pilot study published in the Journal of Cosmetic Dermatology highlights a potential advancement in retinol tolerance. Epicutis Skincare’s proprietary TSC molecule (Tetramethylhexadecenyl Succinoyl Cysteine) was found to significantly reduce the irritation, redness, and dryness commonly associated with tretinoin (a prescription-strength retinoid that is much stronger than retinol) use while reinforcing the skin barrier.

The study was a five-day efficacy evaluation with five subjects performed at a third-party CRO (Validated Claim Support, Teaneck, NJ). There were four female and one male participant with a mean age of 35 years, ranging from 31 to 42 years.

The study found that a formulation of 0.5% TSC combined with 0.2% tretinoin reduced erythema (redness) by 68% and improved dryness by 47%, as compared to tretinoin use alone. No adverse events were observed. 

“Altogether, given these initial encouraging results, further study of TSC in a dose-dependent manner in a larger, controlled study is warranted,” the authors of the study concluded.

ID 139310522 © motortion | Dreamstime.com

LEO Pharma, specializing in medical dermatology, presented late-breaking data at the American Academy of Dermatology (ADD) 2025 Annual Meeting showing that delgocitinib cream produced a deep, consistent, and sustained response in a subgroup of patients with moderate to severe chronic hand eczema.

The presentation marked the third consecutive year that LEO Pharma has presented late-breaking data at AAD. Alongside this presentation, new systemic exposure data also was shared for delgocitinib cream at the meeting.

“The data unveiled today further contributes to LEO Pharma’s ever-growing body of scientific evidence for the treatment of moderate to severe [chronic hand eczema],” says Christophe Bourdon, chief executive officer, LEO Pharma, in a release. “Our research and work in [chronic hand eczema] is a testament to our ambition to maintain the broadest global product portfolio in dermatology, and I am proud we can share this latest analysis from our pivotal DELTA trials.”

Delgocitinib cream is currently under investigation in the United States.

Late-Breaking Post Hoc Data Analysis

The subgroup analysis presented was based on the treatment response in patients with moderate to severe chronic hand eczema treated with delgocitinib cream for 16 weeks compared to patients treated with the cream vehicle in the DELTA 1 and DELTA 2 trials. The subgroup in this analysis was defined as patients with either a deep, consistent and/or maintained treatment response.

The findings from the post hoc analysis highlight that delgocitinib cream produced a strong treatment response across this subgroup of patients.

A deep response, defined as a Hand Eczema Symptom Diary (HESD) itch of 0 (clear) or 1 (almost clear), HESD pain 0/1, and/or a Dermatology Life Quality Index (DLQI) score of 0/1 at week 16, was achieved by more patients receiving delgocitinib cream versus the cream vehicle. At Week 16, 30.0% vs 9.4% of patients achieved a HESD itch of 0/1, 35.2% vs 16.0% achieved HESD pain 0/1, and 33.3% vs 13.9% achieved a DLQI score of 0/1.

Greater percentages of patients receiving delgocitinib cream versus the cream vehicle over the trial period achieved a consistent response of at least a 4-point reduction from baseline in HESD itch (24.1% vs. 6.6%) or pain (25.0% vs. 9.0%) or at least 75% improvement on the Hand Eczema Severity Index (HECSI-75) (27.3% vs. 8.1%).

A maintained response was defined as achieving an Investigator’s Global Assessment (IGA)-CHE of 0 (clear) at week 16 and maintaining IGA-CHE 0 off treatment. Among patients receiving delgocitinib cream who achieved an IGA-CHE score of 0 at week 16, 32.9% maintained a score of 0 after 8 weeks and 15.7% after 16 weeks.

“It is so exciting to see such a strong response in a subgroup of patients treated with delgocitinib cream,” says April W Armstrong, MD, professor and chief of dermatology at the University of California-Los Angeles, in a release. “The results across the various treatment metrics are promising and demonstrate the future potential that delgocitinib cream may have in offering a new treatment option for those living with this unique and burdensome disease.”

Systemic Exposure Analysis

Alongside the late-breaker presentation, new systemic exposure data from the DELTA 2 trial were presented as an e-poster. The data was based on an investigation into the systemic exposure of twice-daily delgocitinib cream under high-use conditions in the phase 3 DELTA 2 trial in adults with moderate to severe chronic hand eczema.

Additionally, the systemic exposure from the DELTA 2 trial was compared with adult pharmacokinetics (PK) data from a phase 1 trial in patients with moderate to severe AD, and with oral administration using the lowest dose tested in an oral PK study in healthy adults.

The DELTA 1, 2 and 3 Trials

The primary objective for the randomized, double-blind, vehicle-controlled, multi-center phase 3 clinical trials (DELTA 1 and DELTA 2) was to evaluate the efficacy of twice-daily applications of delgocitinib cream compared with the cream vehicle in the treatment of adults with moderate to severe chronic hand eczema.

The primary endpoint of the trials was the Investigator’s Global Assessment for chronic hand eczema treatment success (IGA-CHE TS) at week 16. Treatment success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline. Additional IGA-CHE scores included 2 (mild), 3 (moderate), and 4 (severe).

Key secondary endpoints at week 16 included a reduction of itch and pain scores of ≥4 points measured by the Hand Eczema Symptom Diary from baseline to week 16, as well as at least 75% improvement from baseline and at least 90% improvement from baseline on the Hand Eczema Severity Index at week 16. The number of treatment-emergent adverse events from baseline to week 16 defined the key safety endpoint of the trials.

Subjects who completed 16 weeks of treatment with delgocitinib cream or the cream vehicle twice daily in trials DELTA 1 or DELTA 2 were offered to roll over to the 36-week DELTA 3 open-label, multi-site extension trial. The purpose of this extension trial was to evaluate the long-term safety of delgocitinib.

Delgocitinib Cream

Delgocitinib cream is currently under investigation in the United States and other markets. Delgocitinib cream is currently approved in the European Union, United Kingdom, Switzerland, and the United Arab Emirates under the brand name Anzupgo for the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate.

Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe chronic hand eczema. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of chronic hand eczema. The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.

Chronic hand eczema is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. 

ID 140715842 © Olga Ternavskaia | Dreamstime.com

Related Read:

Medical aesthetic device company Candela Corporation announced the global launch of the Glacē solution at the 2025 American Academy of Dermatology (AAD) Annual Meeting, inspired by the K-beauty trend for “glass skin”—a smooth, poreless, and radiant complexion.

The Glacē treatment combines hydrodermabrasion, dual-mode cupping massage, and LED technology to deliver skin purification and hydration. Glacē incorporates dual-mode cupping massage, offering two modes—one to support lymphatic drainage and natural detoxification and another that provides a temporarily sculpted look. Its customizable two-phase serum system delivers tailored treatments for various skin types and concerns, including acne, sensitivity, dryness, uneven tone, and signs of aging. 

Treatment can be performed as a standalone procedure or integrated with energy-based devices (EBDs).

“With the growing demand for natural and non-invasive treatments, the launch of the Glacē treatment marks an exciting milestone for Candela. As our first solution to integrate a broad range of cosmeceuticals for comprehensive skin health, Glacē treatments can be delivered standalone or in combination with our advanced energy-based technologies using Candela-developed protocols,” says Geoff Crouse, CEO of Candela, in a release.

Based on clinical studies, the Glacē treatment demonstrates:

• 100% of subjects reporting visibly cleaner skin,
• 97% experiencing improved hydration, and
• 92% choosing to return for future treatments.

The Glacē treatment made its global debut at the AAD Annual Meeting in Orlando, Fla. It is now commercially available for sale in the US, Europe, Africa, and the Middle East, with availability expanding across Asia Pacific beginning later this month.

Photo caption: Glacē Treatment

Photo credit: Candela Corporation

skinbetter science, available exclusively through dermatology, plastic surgery, and medical aesthetics practices nationwide, announced the launch of BioRewind, a skin health dietary supplement to improve visible skin quality by helping reduce advanced glycation endproducts (AGEs).   

Glycation is a natural process where sugars bind to proteins, such as collagen and elastin, forming harmful substances called AGEs, which can stiffen these proteins and accelerate visible signs of aging. Without intervention, glycated collagen accumulates at an average annual rate of 3.7%. 

BioRewind leverages proprietary CORExtract biotechnology comprised of rosemary extract and bioactive co-factors which help reverse the cumulative effects of early-stage glycation and skin aging at the source.

“The launch of BioRewind marks a significant milestone for skinbetter science and medical grade skincare,” says Jonah Shacknai, CEO of skinbetter science, in a release. “With BioRewind, we are introducing a new approach to counteract skin aging by addressing glycation, a lesser-known but extremely critical factor in the skin aging process. We are confident this innovation will redefine how we think about skin health.”

Clinical Trial Findings

A double-blinded, randomized, placebo-controlled trial evaluated the safety and efficacy of BioRewind in 104 patients over 12 weeks. Key results showed that after 12 weeks, patients in the BioRewind treatment group experienced significant reductions compared to baseline:

• 30% reduction in rough skin texture
• 28% reduction in skin dullness
• 14% reduction in skin redness

Additionally, at 12 weeks a 17%  improvement in global skin quality was achieved in patients in the BioRewind treatment group compared to their baseline measurements. All of the results were statistically significant.

Clinical and histological evidence will be available at the upcoming American Academy of Dermatology Meeting and will be forthcoming in the March issue of the Journal of Clinical and Aesthetic Dermatology. Study co-authors Zoe Diana Draelos, MD, FAAD, and Giuseppe Valacchi, PhD, will present their research at the L’Oréal R&I Theatre on March 8.

BioRewind is designed to be incorporated into an individual’s daily routine. “The process and impact differs dramatically from typical topical treatments on the market because it works from the inside-out,” says Vivian Bucay, MD, FAAD, Bucay Center for Dermatology & Aesthetics, in a release. “This rosemary-based product is free of gluten, colorants, and dyes. My patients are excited to see results within just a few months by simply adding this into their existing skinbetter routine.”

Christian Bouchard, president of medical aesthetic skincare, North America, at L’Oréal, adds in a release, “This breakthrough formula is a game changer for skinbetter science and for our industry. By targeting glycation, BioRewind enhances the skin’s appearance and is an invaluable tool for dermatologists aiming to offer comprehensive solutions to their patients.”

Summary:

skinbetter science has launched BioRewind, a skin health dietary supplement designed to reduce advanced glycation endproducts (AGEs), which contribute to skin aging by stiffening collagen and elastin. The supplement uses proprietary CORExtract biotechnology, featuring rosemary extract and bioactive co-factors, to counteract early-stage glycation and improve skin texture, radiance, and overall quality. A 12-week clinical trial with 104 participants showed significant improvements in skin roughness, dullness, and redness. BioRewind is available exclusively through dermatology, plastic surgery, and medical aesthetics practices, with clinical findings to be presented at the American Academy of Dermatology Meeting and published in The Journal of Clinical and Aesthetic Dermatology.

Key Takeaways:

• Clinical Trial Supports Efficacy – A randomized controlled study showed BioRewind improved skin texture by 30%, reduced dullness by 28%, and decreased redness by 14% over 12 weeks.
• Targets Glycation for Skin Health – The supplement is designed to counteract glycation, a lesser-known but key factor in skin aging, by using a proprietary rosemary-based formula.
• Available Through Select Providers – BioRewind is distributed exclusively through dermatology, plastic surgery, and medical aesthetics practices.

Photo caption: BioRewind

Photo credit: skinbetter science

Key Takeaways:

• VAMP is designed to enhance skin firmness, tighten pores, and smooth wrinkles, leveraging PDRN’s regenerative properties.
• Recommended for professional administration alongside dermal rolling, microneedling, or post-laser treatments to maximize its rejuvenating effects.

Prollenium, a medical aesthetics company, announced the launch of VAMP, a skin revitalization product. According to a press release from the company, this topical, sterile bio-revitalizing solution combines an enriched blend of vitamins, amino acids, minerals, and polydeoxyribonucleotides (PDRN) to deliver anti-aging, hydrating, and revitalizing benefits.

VAMP is formulated to enhance skin tonicity, tighten pores, and smooth wrinkles, according to the company. PDRN, an ingredient derived from salmon DNA and popularized in K-beauty, reportedly offers advanced anti-aging, rejuvenating, and hydrating properties. The company says VAMP utilizes these benefits to stimulate and promote tissue repair, resulting in firmer, smoother, and more rejuvenated skin. It is recommended that VAMP be professionally administered in conjunction with dermal rolling, microneedling, or post-laser treatments.

The launch of this skin rejuvenating solution marks the first addition to Prollenium’s expanding portfolio of innovative skin technologies and products. It joins brands REVANESSE and SoftFil, which are available in more than 70 countries worldwide. According to the company, VAMP reflects its recently announced strategic focus on leveraging advanced technology and R&D to drive the future of skin rejuvenation innovations.

“We are at a pivotal moment in our industry, with science and innovation accelerating our ability to support the skin’s natural repair and rejuvenation processes. VAMP is the first PDRN product to combine vitamins, amino acids, and minerals with PDRN to deliver powerful anti-aging, hydrating, and rejuvenating benefits. This launch represents our commitment to innovation in restorative medicine for aesthetic dermatology,” said Ario Khoshbin, founder and CEO of Prollenium.

“The growing demand for combination therapies and rejuvenating solutions is transforming our industry,” added Khoshbin. “Our strength lies in leveraging advanced technology and our multidisciplinary team of scientists to develop products that address the root causes of skin aging. This expertise led to the development of VAMP, a breakthrough in PDRN products. We look forward to expanding on this innovation with comprehensive treatment options.”

Photo courtesy of Prollenium.